Medical device company Vitrolife AB (STO:VITR) announced on Friday the receipt of market approval for the time-lapse incubator EmbryoScope+ in the US, considered the world's third largest market measured in terms of number of IVF treatments.
EmbryoScope+ is a time-lapse system with an integrated incubator with a capacity for 15 patients. Vitrolife is a market leader of time-lapse systems for use in assisted reproduction for undisturbed culture and improved selection of embryos.
With this approval, Vitrolife will be able to offer EmbryoScope+ to clinics in US.
Vitrolife develops, produces and markets medical devices for assisted reproduction.
Crossject advances paediatric development of ZEPIZURE Junior for epilepsy crisis management
Creo Medical secures FDA clearance for SpydrBlade Flex in US market
Tissue Regenix secures CE and UKCA certifications for OrthoPure XT
Terumo Corporation expands stroke portfolio in EMEA with SOFIA Flow 88 catheter launch
Crossject advances ZENEO manufacturing with scalable aseptic filling module ahead of product rollout
ZYLOX Unicorn Vascular Closure Device approved in Indonesia
Mindray unveils BeneVision V Series at Euroanaesthesia 2025, advancing precision monitoring
Unicon Pharma and VRR Life Sciences partner support digital transformation in life sciences
Median Technologies submits 510(k) application for eyonis LCS lung cancer screening software